Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we look at the FDA’s interest in botanical drugs, the persistent barriers to clozapine use, and the ways in which pig kidneys could bridge patients to human transplants.
No better place than a SoCal gym to unfurl the mechanics of unapproved peptide trafficking. Trust me.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
